Evidence map›Paper›PMID 42449556›Full record

Observational studyCancer medicine2026

Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study.

Erica C Koch Hein, Abha Gupta, Hagit Peretz Soroka, Caroline Holloway, Brookelyn Biffart, Carolyn Nessim, Tristan Wild, Katherine Lajkosz, Geoffrey A Watson, Albiruni Abdul Razak and 1 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erica C Koch HeinDivision of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Abha GuptaDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Hagit Peretz SorokaDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Caroline HollowayDivision of Radiation Oncology, BC Cancer, University of British Columbia, Victoria, British Columbia, Canada.ORCID https://orcid.org/0000-0003-3089-2006
Brookelyn BiffartDivision of Radiation Oncology, BC Cancer, University of British Columbia, Victoria, British Columbia, Canada.
Carolyn NessimDepartment of Surgery, The Ottawa Hospital and Research Institute, University of Ottawa, Ottawa, Canada.
Tristan WildDepartment of Surgery, The Ottawa Hospital and Research Institute, University of Ottawa, Ottawa, Canada.
Katherine LajkoszDepartment of Biostatistics, University Health Network, Toronto, Canada.
Geoffrey A WatsonDivision of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Albiruni Abdul RazakDivision of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Abdulazeez SalawuDivision of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-4420-0958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFrontline systemic treatment selection for advanced leiomyosarcoma (LMS) remains variable in routine practice. Gemcitabine-based regimens are frequently used despite randomized evidence of non-superiority compared with doxorubicin-based regimens and greater complexity in treatment delivery.

methodsThis multi-centre retrospective cohort study included advanced/metastatic LMS patients treated with frontline doxorubicin- or gemcitabine-based chemotherapy at four Canadian sarcoma centres (2010-2022). The primary endpoint was overall survival (OS). Secondary endpoints were time to second-line treatment (T2T) and number of subsequent systemic treatment lines. Subgroup analyses were conducted by primary tumor site (uterine vs. non-uterine LMS).

resultsAmong 217 patients, median OS was 17.1 months (95% CI 14.8-21.1). OS did not differ between frontline doxorubicin- and gemcitabine-based regimens (17.8 vs. 16.1 months; p = 0.16), nor did T2T (5.8 vs. 6.3 months; p = 0.77). Non-uterine primary site and surgery following frontline systemic treatment were independently associated with improved OS. Median OS was longer for non-uterine versus uterine LMS (23 vs. 12.8 months; p < 0.001).

conclusionsIn this large real-world LMS cohort, outcomes were not influenced by frontline chemotherapy choice. These findings support prioritizing toxicity, quality of life, cost, and treatment delivery burden when selecting frontline therapy, particularly where doxorubicin/trabectedin use is limited.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeiomyosarcomaUterine NeoplasmsAdultAgedCanadaDeoxycytidineDoxorubicinFemaleGemcitabineHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeDeoxycytidineDoxorubicinGemcitabinechemotherapydoxorubicingemcitabineleiomyosarcoma

Identifiers

PMID42449556
PMCPMC13369297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.